Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T
Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the start of a pivotal trial approximately six months to better understand how HLA matching potentially affects efficacy.